Prenetics Global Ltd (PRE) - Net Assets
Based on the latest financial reports, Prenetics Global Ltd (PRE) has net assets worth $161.20 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($196.51 Million) and total liabilities ($35.30 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Prenetics Global Ltd balance sheet assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $161.20 Million |
| % of Total Assets | 82.03% |
| Annual Growth Rate | -9.89% |
| 5-Year Change | 452.6% |
| 10-Year Change | -97.53% |
| Growth Volatility | 307.0 |
Prenetics Global Ltd - Net Assets Trend (2000–2024)
This chart illustrates how Prenetics Global Ltd's net assets have evolved over time, based on quarterly financial data. Check Prenetics Global Ltd tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Prenetics Global Ltd (2000–2024)
The table below shows the annual net assets of Prenetics Global Ltd from 2000 to 2024. For live valuation and market cap data, see Prenetics Global Ltd market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $171.35 Million | -18.47% |
| 2023-12-31 | $210.16 Million | -13.68% |
| 2022-12-31 | $243.46 Million | +160.73% |
| 2021-12-31 | $-400.89 Million | -1392.92% |
| 2020-12-31 | $31.01 Million | +83.99% |
| 2019-12-31 | $16.85 Million | -99.76% |
| 2015-12-31 | $6.90 Billion | -2.84% |
| 2014-12-31 | $7.10 Billion | +5.00% |
| 2013-12-31 | $6.77 Billion | -2.41% |
| 2012-12-31 | $6.93 Billion | +7.20% |
| 2011-12-31 | $6.47 Billion | -10.26% |
| 2010-12-31 | $7.21 Billion | -5.74% |
| 2009-12-31 | $7.65 Billion | +82.08% |
| 2008-12-31 | $4.20 Billion | -2.83% |
| 2007-12-31 | $4.32 Billion | +14.15% |
| 2006-12-31 | $3.79 Billion | +22.41% |
| 2005-12-31 | $3.09 Billion | -7.73% |
| 2004-12-31 | $3.35 Billion | +29.20% |
| 2003-12-31 | $2.59 Billion | +24.90% |
| 2002-12-31 | $2.08 Billion | +18.82% |
| 2001-12-31 | $1.75 Billion | -16.20% |
| 2000-12-31 | $2.09 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Prenetics Global Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 145.6% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $19.00K | 0.01% |
| Other Comprehensive Income | $-169.25 Million | -99.33% |
| Other Components | $856.69 Million | 502.79% |
| Total Equity | $170.39 Million | 100.00% |
Prenetics Global Ltd Competitors by Market Cap
The table below lists competitors of Prenetics Global Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tien Phong Securities Corp
VN:ORS
|
$317.65 Million |
|
International CSRC Investment Holdings Co Ltd
TW:2104
|
$317.83 Million |
|
Shenzhen Fluence Technology PLC
SHE:300647
|
$317.87 Million |
|
Shanghai Information2 Software Inc. A
SHG:688435
|
$317.93 Million |
|
Alpine Income Property Trust, Inc.
NYSE:PINE
|
$317.50 Million |
|
JSL S.A
SA:JSLG3
|
$317.49 Million |
|
Baillie Gifford European Growth Trust PLC
LSE:BGEU
|
$317.48 Million |
|
Taeyoung Engineering & Construction Co.,Ltd.
KO:009410
|
$317.43 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Prenetics Global Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 206,359,000 to 170,389,000, a change of -35,970,000 (-17.4%).
- Net loss of 46,304,000 reduced equity.
- Share repurchases of 577,000 reduced equity.
- Other comprehensive income increased equity by 6,779,000.
- Other factors increased equity by 4,132,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-46.30 Million | -27.18% |
| Share Repurchases | $577.00K | -0.34% |
| Other Comprehensive Income | $6.78 Million | +3.98% |
| Other Changes | $4.13 Million | +2.43% |
| Total Change | $- | -17.43% |
Book Value vs Market Value Analysis
This analysis compares Prenetics Global Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.55x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.34x to 1.55x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | $60.94 | $20.83 | x |
| 2005-12-31 | $56.23 | $20.83 | x |
| 2006-12-31 | $65.27 | $20.83 | x |
| 2007-12-31 | $74.51 | $20.83 | x |
| 2008-12-31 | $74.98 | $20.83 | x |
| 2009-12-31 | $119.46 | $20.83 | x |
| 2010-12-31 | $92.40 | $20.83 | x |
| 2011-12-31 | $95.11 | $20.83 | x |
| 2012-12-31 | $108.34 | $20.83 | x |
| 2013-12-31 | $119.81 | $20.83 | x |
| 2014-12-31 | $0.00 | $20.83 | x |
| 2015-12-31 | $0.00 | $20.83 | x |
| 2019-12-31 | $2.29 | $20.83 | x |
| 2020-12-31 | $4.20 | $20.83 | x |
| 2021-12-31 | $-108.35 | $20.83 | x |
| 2022-12-31 | $46.76 | $20.83 | x |
| 2023-12-31 | $18.35 | $20.83 | x |
| 2024-12-31 | $13.41 | $20.83 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Prenetics Global Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -27.18%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -151.22%
- • Asset Turnover: 0.14x
- • Equity Multiplier: 1.25x
- Recent ROE (-27.18%) is below the historical average (-5.39%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 6.82% | 9.33% | 0.25x | 2.92x | $-66.29 Million |
| 2002 | 9.16% | 7.13% | 0.31x | 4.21x | $-17.42 Million |
| 2003 | 18.03% | 12.08% | 0.36x | 4.20x | $208.24 Million |
| 2004 | 14.69% | 11.80% | 0.33x | 3.73x | $157.17 Million |
| 2006 | 19.79% | 17.89% | 0.28x | 3.95x | $370.75 Million |
| 2007 | 16.61% | 17.29% | 0.26x | 3.71x | $285.66 Million |
| 2008 | 1.11% | 1.16% | 0.25x | 3.88x | $-373.34 Million |
| 2009 | 20.10% | 28.81% | 0.22x | 3.10x | $772.28 Million |
| 2010 | 11.83% | 14.44% | 0.25x | 3.24x | $131.86 Million |
| 2012 | 16.36% | 20.40% | 0.24x | 3.31x | $441.16 Million |
| 2013 | 9.90% | 11.88% | 0.24x | 3.43x | $-6.95 Million |
| 2014 | 14.97% | 16.29% | 0.29x | 3.16x | $350.08 Million |
| 2015 | 1.51% | 1.91% | 0.26x | 3.10x | $-585.67 Million |
| 2019 | -119.14% | -218.15% | 0.31x | 1.76x | $-21.83 Million |
| 2020 | -6.24% | -2.98% | 0.83x | 2.54x | $-5.05 Million |
| 2021 | 0.00% | -1388.44% | 0.08x | 0.00x | $-133.93 Million |
| 2022 | -80.34% | -1446.78% | 0.04x | 1.32x | $-214.16 Million |
| 2023 | -30.40% | -288.48% | 0.09x | 1.23x | $-83.36 Million |
| 2024 | -27.18% | -151.22% | 0.14x | 1.25x | $-63.34 Million |
Industry Comparison
This section compares Prenetics Global Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $564,598,330
- Average return on equity (ROE) among peers: -181.03%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Prenetics Global Ltd (PRE) | $161.20 Million | 6.82% | 0.22x | $317.60 Million |
| Agilent Technologies Inc (A) | $4.57 Billion | 6.91% | 0.87x | $36.87 Billion |
| Advanced Biomed Inc. Common Stock (ADVB) | $976.24K | -188.19% | 0.03x | $8.80 Million |
| Applied DNA Sciences Inc (APDN) | $756.92K | -944.71% | 0.78x | $3.99 Million |
| Biodesix Inc (BDSX) | $-2.46 Million | 0.00% | 0.00x | $205.15 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $3.14 Million |
| Biocept Inc. (BIOCQ) | $8.86 Million | -362.16% | 2.48x | $262.60 |
| BillionToOne, Inc. Class A Common Stock (BLLN) | $30.47 Million | -271.32% | 5.29x | $4.57 Billion |
| Burning Rock Biotech Ltd (BNR) | $535.60 Million | -10.33% | 0.53x | $87.85 Million |
| CareDx Inc (CDNA) | $465.88 Million | -6.58% | 0.22x | $1.42 Billion |
| Check Cap Ltd (CHEK) | $50.69 Million | -33.94% | 0.10x | $9.42 Million |
About Prenetics Global Ltd
Prenetics Global Limited, a health sciences company, focuses on advancing consumer health in Hong Kong, the United States, and internationally. It sells health and wellness products under the IM8 brand name; and provides fulfillment and distribution services for sports nutrition products under the Europa brand. The company is also involved in the operation of CircleDNA, a consumer genetic testing… Read more